488834-75-9

Basic information

• Product Name: (6-HYDROXYMETHYL)QUINOXALINE
• Synonyms: RARECHEM AM LA 0029;(6-HYDROXYMETHYL)QUINOXALINE;6-Quinoxalinemethanol
• CAS NO: 488834-75-9
• Molecular Formula: C₉H₈N₂O
• Molecular Weight: 160.17
• Product Categories: Building Blocks;Quinoxaline
• Mol File: 488834-75-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 340.7 °C at 760 mmHg
• Flash Point: 159.9 °C
• Appearance: /
• Density: 1.293 g/cm³
• Vapor Pressure: 3.26E-05mmHg at 25°C
• Refractive Index: 1.678
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (6-HYDROXYMETHYL)QUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: (6-HYDROXYMETHYL)QUINOXALINE(488834-75-9)
• EPA Substance Registry System: (6-HYDROXYMETHYL)QUINOXALINE(488834-75-9)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 488834-75-9(Hazardous Substances Data)

Usage

Uses

Quinoxalin-6-ylmethanol is a useful chemical for the preparation of quinoline and quinoxaline analogs of combretastatins.

InChI:InChI=1/C9H8N2O/c12-6-7-1-2-8-9(5-7)11-4-3-10-8/h1-5,12H,6H2

Upstream product

• 6925-00-4 quinoxaline-6-carboxylic acid 
• 6344-72-5 6-methylquinoxaline 
• 53967-21-8 6-bromomethyl-quinoxaline 
• 619-05-6 3,4-diaminobenzoic acid 

Downstream Products

• 473895-88-4 6-Hydroxymethyl-methyl-quinoxaline 
• 130345-50-5 quinoxaline-6-carbaldehyde 
• 1357063-34-3 (2E)-1-phenyl-3-(quinoxalin-6-yl)-2-propen-1-one 
• 1357063-32-1 (2E)-1-(4-methoxyphenyl)-3-(quinoxalin-6-yl)prop-2-en-1-one 
• 1357063-37-6 (2E)-1-(3,4-dimethoxyphenyl)-3-(quinoxalin-6-yl)prop-2-en-1-one 
• 1357063-36-5 (2E)-1-(2,5-dimethoxyphenyl)-3-(quinoxalin-6-yl)prop-2-en-1-one 
• 1357063-35-4 (2E)-1-(4-nitrophenyl)-3-(quinoxalin-6-yl)prop-2-en-1-one 
• 1355970-56-7 (2E)-1-(4'-bromophenyl)-3-(quinoxalin-6-yl)-2-propen-1-one 

Relevant articles and documents

Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation

Gliomas are the most common and devastating tumors of the central nervous system (CNS). Many pieces of evidence point out the relevance of natural compounds for cancer therapy and prevention, including chalcones. In the present study, eight synthetic quin

Methods for preparing 5- and 6-benzyl-functionalized quinoxalines

The present invention pertains to methods for preparing 5- and 6-benzyl functionalized quinoxalines. In a first embodiment, the method comprises contacting an aqueous suspension of a 5- and 6-halomethyl quinoxaline with a water-soluble nucleophile. In a second embodiment, the method comprises contacting a 5- and 6-halomethyl quinoxaline with an organic solvent-soluble nucleophile in an inert polar organic solvent. In a third embodiment, the method comprises contacting a 5- and 6-halomethyl quinoxaline in an organic solvent with an aqueous solution of a water-soluble nucleophile in the presence of a phase transfer catalyst.